Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab and Retinal Vascular Occlusions

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00347711
First received: June 30, 2006
Last updated: July 3, 2006
Last verified: June 2006

June 30, 2006
July 3, 2006
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bevacizumab and Retinal Vascular Occlusions
Not Provided
To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
  • Edema Macular
  • Vascular Occlusion
Drug: Intravitreal injection
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Vascular occlusion and edema macular diagnosticated by fluorescein angiography and coherent optic tomography

Exclusion Criteria:

  • Previous surgery
  • Uveitis
  • Glaucoma
Both
40 Years to 90 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT00347711
APEC-0020
Not Provided
Not Provided
Not Provided
Not Provided
Asociación para Evitar la Ceguera en México
Not Provided
Principal Investigator: Griselda Alvarez, Fellow APEC
Asociación para Evitar la Ceguera en México
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP